MEDVi
MEDVi is a direct-to-consumer telehealth platform founded in 2024 that prescribes compounded GLP-1 weight loss medications and erectile dysfunction treatments through partner physicians and compounding pharmacies, generating $401 million in revenue in its first full year.
- Company typePrivate
- Founded2024
- HeadquartersNewark, United States
- Headcount1–10
- GTM typeB2C
- OfferingServices
What MEDVi does
MEDVi is a direct-to-consumer telehealth platform founded in September 2024 by Matthew Gallagher that delivers compounded GLP-1 weight-loss medications (semaglutide and tirzepatide) at price points materially below FDA-approved alternatives — $179 first month / $299 monthly for injectable semaglutide, $249 monthly for oral semaglutide, and $349 monthly for tirzepatide injectable — alongside branded Wegovy/Ozempic/Zepbound offered at $99 membership plus medication cost. The platform operates an online intake and prescription workflow routed to partner physicians (OpenLoop Health, CareGLP affiliated PCs) and fulfillment by licensed compounding pharmacies (Triad Rx, RedRock Pharmacy, Beaker Pharmacy), with services available across a subset of US states.
The company is built on an AI-orchestrated operating model in which more than a dozen AI tools handle coding, marketing content production, customer service chatbots, and business analytics, allowing the platform to run with just two employees and $20,000 in initial capital. The product catalog has expanded beyond weight loss into MEDVi QUAD (a 4-in-1 compounded erectile dysfunction medication), peptides and longevity, women's health, hair restoration, skincare, supplements, and MEDVi Meals (a chef-prepared meal delivery service targeting GLP-1 patients). Customer acquisition is driven primarily by affiliate marketers running paid ads on Meta, with reported use of AI-generated doctor profiles in promotional content.
In its first full year of operation (2025), MEDVi reported $401 million in revenue and $65 million in profit (16.2% net margin) on a base of approximately 250,000 customers, with $1.8 billion projected for 2026 (NYT-verified financials). The company is currently subject to an FDA warning letter issued February 2026 regarding GLP-1 marketing practices, multiple lawsuits alleging AI-generated fake doctor profiles (including a Dr. Anderson likeness suit), class action claims around spam/TCPA violations, and a consumer advocacy group request for FTC investigation — all of which represent material regulatory and reputational risk to the core compounded-GLP-1 revenue stream.
MEDVi firmographics
Firmographics- Name
- MEDVi
- Legal name
- MEDVi, LLC
- Website
- https://medvi.org
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- MEDVi is a direct-to-consumer telehealth platform founded in 2024 that prescribes compounded GLP-1 weight loss medications and erectile dysfunction treatments through partner physicians and compounding pharmacies, generating $401 million in revenue in its first full year.
- Ownership category
- akta.pro rank
MEDVi industry classification
Industry- Product category
- Direct-to-Consumer Telehealth
- NAICS
- Offices of Physicians (6211)
- SIC
- Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)
- akta.pro primary industry
- Prescription-Based Digital Clinics (Condition-Specific Rx Programs) (HLALAAAD)
- akta.pro secondary industries
- Healthcare On‑Demand Platforms (Telehealth, Home Care, Nursing) (BPAMAHAH), Chronic Condition Medication Programs (e.g., diabetes, hypertension) with Integrated Prescribing (HLALAIAH)
Keywords
Where MEDVi is headquartered
LocationHeadquarters
- HQ city
- Newark
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
MEDVi business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Marketing or Sales, Operations, Technology or R&D, Personnel, Infrastructure
Revenue model
- GLP-1 Weight Loss Program Subscriptions: Monthly subscription model for compounded GLP-1 medications (semaglutide and tirzepatide) with pricing at $179 first month and $299 monthly thereafter. Revenue is recurring subscription-based with auto-renewing memberships.
- MEDVi QUAD ED Medication: Subscription-based sale of compounded erectile dysfunction medication combining sildenafil, tadalafil, vardenafil, and apomorphine. Priced starting at approximately $114-$119 per month.
- Wegovy and Brand Medications: Sale of FDA-approved medications including Wegovy at $99 membership plus medication cost. Ozempic and Zepbound also available at higher price points.
- Affiliate Marketing Revenue: Significant revenue driven by affiliate marketers who promote products and earn commissions on referred customers.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | GLP-1 Semaglutide Injections - First Month |
| Subscription | Monthly | GLP-1 Semaglutide Injections - Ongoing |
| Subscription | Monthly | GLP-1 Semaglutide Tablets |
| Subscription | Monthly | Tirzepatide Injections |
| Subscription | Monthly | Tirzepatide Tablets |
| Subscription | Monthly | Wegovy Pill - Membership Plus Medication |
| Subscription | Monthly | Ozempic/Zepbound Injections |
| Subscription | Monthly | MEDVi QUAD - Most Popular Tier |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
MEDVi product offering
Product offeringCore offering
MEDVi operates a direct-to-consumer telehealth platform that evaluates patients online and dispenses compounded GLP-1 weight-loss medications (semaglutide and tirzepatide, oral and injectable), the proprietary MEDVi QUAD 4-in-1 erectile dysfunction therapy, peptide and longevity treatments, women's health programs, supplements, and MEDVi Meals portion-controlled nutrition. Each program bundles physician consultation, prescription, ongoing coaching, 24/7 support, and home delivery on a recurring monthly subscription.
Differentiator
Problem solved
Functional benefit
Brands
- MEDVi Meals: Chef-made, portion-controlled meal delivery service designed to support GLP-1 weight loss journey
- MEDVi QUAD
Products and services
- GLP-1 Weight Loss Program (Compounded Semaglutide and Tirzepatide) Doctor-supervised, subscription-based weight-loss program delivered through the MEDVi telehealth platform; includes online intake, physician evaluation, prescription of compounded GLP-1 medication (semaglutide or tirzepatide, injectable or oral) shipped to the patient's door, 1:1 physician guidance, free dietician visits, care coaching, and 24/7 support. Targeted at US adults without insurance coverage for FDA-approved weight-loss drugs.
- MEDVi QUAD Erectile Dysfunction Treatment Subscription-based, compounded erectile dysfunction medication combining sildenafil, tadalafil, vardenafil, and apomorphine into a single sublingual rapid-absorb dose, with online physician consultation, free rush shipping, and 24/7 support; positioned as a comprehensive alternative to single-ingredient PDE5 inhibitors for US men with ED.
- MEDVi Meals
Quantifiable outcome
- 18% average body weight loss for patients on GLP-1 treatment over first 6 months
- +3 more outcomes
Companies that use MEDVi
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles2 records
MEDVi technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature3 records
MEDVi partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core.
- OpenLoop HealthcoreNetwork of US-licensed doctors providing clinical services for MEDVi patients. OpenLoop Health adheres to rigorous medical protocols designed for patient safety and conducts telehealth consultations and determines prescription eligibility.
- CareGLP Affiliated P.C.scoreAffiliated professional corporations providing medical treatment services through the MEDVi platform. These entities employ or contract with licensed healthcare providers.
- Triad RxcorePartner pharmacy dispensing compounded medications. Located at 26258 Pollard Rd, Daphne, AL 36526. One of multiple certified pharmacies in MEDVi's network.
- RedRock PharmacycorePartner pharmacy fulfilling prescriptions. Located at 1240 E 100 S #220, St. George, UT 84790. Certified pharmacy providing medication preparation and shipping.
- Beaker Pharmacy & CompoundingcoreCompounding pharmacy partner preparing customized medications. Located at 7810 Eldorado Pkwy STE 200, McKinney, TX 75072.
- Affiliate MarketerscoreThird-party affiliate marketers who run paid advertisements promoting MEDVi products. These affiliates have been the subject of controversy for using AI-generated fake doctor profiles in advertisements.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
MEDVi competitors and assessment
Company assessmentDirect peers
- Ro: Ro operates a DTC telehealth platform that includes Ro Body (GLP-1 weight loss) and Roman (men's health/ED). Directly comparable to MEDVi's core weight-loss and men's health subscription offerings.
- Hims & Hers Health: Hims & Hers is a publicly-traded DTC telehealth platform offering GLP-1 weight-loss programs along with men's and women's health. Direct competitor to MEDVi across weight loss, ED, and broader telehealth subscription verticals.
- Sesame: Sesame is a DTC telehealth marketplace offering weight-loss consultations and prescriptions at transparent cash-pay pricing. Comparable business model of online intake, physician review, and direct medication delivery.
- Mochi Health: Mochi Health is a telehealth platform offering GLP-1 weight-loss programs with physician visits and compounded medication fulfillment. Targets the same price-sensitive consumer cohort as MEDVi.
- LifeMD: LifeMD is a telemedicine company with a direct-to-consumer GLP-1 weight-loss program. Competes head-to-head with MEDVi on compounded GLP-1 telehealth subscriptions.
- Henry Meds: Henry Meds is a DTC telehealth provider of compounded GLP-1 weight-loss medications with a similar cost-leadership, subscription-based model. Closest analog to MEDVi in the compounded-GLP-1 telehealth niche.
- Noom Med: Noom Med is the prescription/telehealth arm of Noom, providing GLP-1 medications alongside behavior-change coaching. Directly comparable to MEDVi's combination of physician-guided GLP-1 therapy and ongoing support.
Broad incumbents
- WeightWatchers (WW): WeightWatchers has expanded into compounded GLP-1 telehealth via its WeightWatchers Clinic program. A larger incumbent with established consumer brand awareness now competing in MEDVi's core GLP-1 telehealth category.
Emerging players
- Lemonaid Health: Lemonaid Health (now part of 23andMe) is an online clinic offering prescription treatments including weight management. Comparable online intake, physician-prescribing, and home-delivery model.
- Found (Found Health): Found is a DTC telehealth platform combining physician-supervised weight management with GLP-1 access. Overlaps MEDVi's weight-loss telehealth offering with a more behavior-coaching-led approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
MEDVi financial estimates
Financial estimateRevenue estimate
Valuation estimate
MEDVi leadership team
Management profileNumber of profiles
Profiles1 record
MEDVi funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MEDVi M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MEDVi
What does MEDVi do?
MEDVi operates a direct-to-consumer telehealth platform that evaluates patients online and dispenses compounded GLP-1 weight-loss medications (semaglutide and tirzepatide, oral and injectable), the proprietary MEDVi QUAD 4-in-1 erectile dysfunction therapy, peptide and longevity treatments, women's health programs, supplements, and MEDVi Meals portion-controlled nutrition. Each program bundles physician consultation, prescription, ongoing coaching, 24/7 support, and home delivery on a recurring monthly subscription.
Is MEDVi a public or private company?
MEDVi is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was MEDVi founded?
MEDVi was founded in 2024. It employs 1 to 10 people.
Where is MEDVi based?
MEDVi is headquartered in Newark, United States, in the North America region.
How does MEDVi make money?
Four revenue lines are on record. GLP-1 Weight Loss Program Subscriptions are the primary driver. The others are MEDVi QUAD ED Medication, wegovy and Brand Medications and affiliate Marketing Revenue.
Who are MEDVi's main competitors?
Direct peers on record are Ro, Hims & Hers Health, Sesame, Mochi Health, LifeMD, Henry Meds and Noom Med. WeightWatchers (WW) is listed as a broad incumbent. Emerging players are Lemonaid Health and Found (Found Health).
Does MEDVi have an API?
No public API is recorded for MEDVi.
What industry is MEDVi in?
MEDVi's product category is Direct-to-Consumer Telehealth. Its primary akta.pro industry code is HLALAAAD, Prescription-Based Digital Clinics (Condition-Specific Rx Programs), with a secondary code of BPAMAHAH, Healthcare On‑Demand Platforms (Telehealth, Home Care, Nursing). Its NAICS code is 6211 and its SIC code is 8011.